Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Neurology|October 13, 2022
Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemicGiuseppe Magro, Stefania Barone, Federico Tosto, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 6, 2018
Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patientsIda Manna, Enrico Iaccino, Vincenzo Dattilo, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 18, 2024
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variablesStefania Barone, Camillo Palmieri, Luca Gallelli, et al.Le Infezioni in Medicina|June 4, 2020
Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?Maria Mazzitelli, Stefania Barone, Giuseppe Greco, et al.Journal of Neurology|May 4, 2024
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched studyAurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 12, 2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison StudyAurora Zanghì, Antonio Gallo, Carlo Avolio, et al.Multiple Sclerosis and Related Disorders|March 26, 2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian studyGiorgia T Maniscalco, Francesco Saccà, Roberta Lanzillo, et al.Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 2, 2019
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experienceChiara Zecca, Francesca Bovis, Giovanni Novi, et al.Pageof 2